Skip to main content

and
  1. No Access

    Article

    Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

    Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according to pancreatic ductal adenocarcinoma (PDAC). Herein, we descri...

    Makiko Urabe, Kenji Ikezawa, Kazuhiro Kozumi in Clinical Journal of Gastroenterology (2024)

  2. No Access

    Article

    Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer

    Although patients with advanced pancreatic cancer (PC) often experience dysgeusia with zinc deficiency during chemotherapy, data on zinc supplementation for dysgeusia and its effects on nutritional status are ...

    Yusuke Seiki, Kenji Ikezawa, Ko Watsuji in International Journal of Clinical Oncology (2024)

  3. No Access

    Article

    Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry

    Pancreatic cancer (PC) has one of the worst prognoses among all solid cancers. Hospital volume has been shown to be significantly associated with outcomes in patients with PC undergoing surgery. Nonetheless, t...

    Yasuharu Kawamoto, Kenji Ikezawa in Journal of Cancer Research and Clinical On… (2023)

  4. Article

    Open Access

    An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study

    The effectiveness of chemotherapy in older adult patients with biliary tract cancer (BTC) remains to be established, despite the fact that the majority of patients diagnosed with BTC tend to be aged ≥ 70 years...

    Takeru Hirao, Kenji Ikezawa, Toshitaka Morishima, Kazuma Daiku in BMC Gastroenterology (2023)

  5. Article

    Open Access

    Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer

    Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV) was approved for unresectable pancreatic cancer (UR-PC) in March 2020 in Japan. Levo-LV is administered by intravenous infus...

    Ryoji Takada, Kenji Ikezawa, Takuo Yamai, Ko Watsuji, Yusuke Seiki in BMC Cancer (2023)

  6. Article

    Open Access

    Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration

    Hepatocellular carcinoma highly occurs in chronic hepatitis livers, where hepatocyte apoptosis is frequently detected. Apoptosis is a mechanism that eliminates mutated cells. Hepatocyte apoptosis induces compe...

    Yasutoshi Nozaki, Hayato Hikita, Satoshi Tanaka, Kenji Fukumoto in Scientific Reports (2021)